JP2023542066A5 - - Google Patents
Info
- Publication number
- JP2023542066A5 JP2023542066A5 JP2022580316A JP2022580316A JP2023542066A5 JP 2023542066 A5 JP2023542066 A5 JP 2023542066A5 JP 2022580316 A JP2022580316 A JP 2022580316A JP 2022580316 A JP2022580316 A JP 2022580316A JP 2023542066 A5 JP2023542066 A5 JP 2023542066A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical product
- product according
- hydrogen
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025258116A JP2026048860A (ja) | 2020-06-24 | 2025-12-17 | 抗体-薬物コンジュゲートとatr阻害剤との組み合わせ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063043498P | 2020-06-24 | 2020-06-24 | |
| US63/043,498 | 2020-06-24 | ||
| PCT/IB2021/055548 WO2021260579A1 (en) | 2020-06-24 | 2021-06-23 | Combination of antibody-drug conjugate and atr inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025258116A Division JP2026048860A (ja) | 2020-06-24 | 2025-12-17 | 抗体-薬物コンジュゲートとatr阻害剤との組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023542066A JP2023542066A (ja) | 2023-10-05 |
| JP2023542066A5 true JP2023542066A5 (cg-RX-API-DMAC7.html) | 2024-06-25 |
| JP7793556B2 JP7793556B2 (ja) | 2026-01-05 |
Family
ID=76730926
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022580316A Active JP7793556B2 (ja) | 2020-06-24 | 2021-06-23 | 抗体-薬物コンジュゲートとatr阻害剤との組み合わせ |
| JP2025258116A Pending JP2026048860A (ja) | 2020-06-24 | 2025-12-17 | 抗体-薬物コンジュゲートとatr阻害剤との組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025258116A Pending JP2026048860A (ja) | 2020-06-24 | 2025-12-17 | 抗体-薬物コンジュゲートとatr阻害剤との組み合わせ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230330243A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4171650A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7793556B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230043109A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116635082A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021298251A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022026205A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3183867C (cg-RX-API-DMAC7.html) |
| IL (1) | IL299368A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022016375A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202216208A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021260579A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121038817A (zh) * | 2023-04-10 | 2025-11-28 | 第一三共株式会社 | 抗-b7-h3抗体-药物缀合物和atr抑制剂或atm抑制剂的组合 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025083071A2 (en) * | 2023-10-16 | 2025-04-24 | Hummingbird Bioscience Pte. Ltd. | Antibody-drug conjugates |
| CN122374045A (zh) * | 2023-10-16 | 2026-07-10 | 蜂鸟生物科技私人有限公司 | Her2结合分子 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| AR024464A1 (es) | 1999-06-25 | 2002-10-02 | Genentech Inc | Anticuerpos anti-erbb2 humanizados. |
| CN103333860B (zh) | 2000-10-06 | 2015-07-08 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
| CA2647632C (en) | 2006-03-27 | 2017-06-27 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| SA111320519B1 (ar) * | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
| JP6282232B2 (ja) | 2012-02-10 | 2018-02-21 | ユニバーシティー オブ メリーランド,ボルティモア | 抗体及びそのFcフラグメントの酵素化学的糖鎖改変 |
| US10195288B2 (en) | 2012-10-11 | 2019-02-05 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate |
| SG10201902571VA (en) | 2013-12-25 | 2019-04-29 | Daiichi Sankyo Co Ltd | Anti-trop2 antibody-drug conjugate |
| SG11201603960XA (en) | 2014-01-31 | 2016-07-28 | Daiichi Sankyo Co Ltd | Anti-her2 antibody-drug conjugate |
| TWI871999B (zh) | 2014-04-10 | 2025-02-01 | 日商第一三共股份有限公司 | 抗her3抗體-藥物結合物 |
| CA2990572C (en) | 2015-06-29 | 2022-07-26 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| TWI926682B (zh) | 2017-05-15 | 2026-05-21 | 日商第一三共股份有限公司 | 抗體-藥物結合物之製造方法 |
| EP3677589B1 (en) | 2017-08-31 | 2025-11-26 | Daiichi Sankyo Company, Limited | Improved method for producing antibody-drug conjugate |
| JP2022505041A (ja) | 2018-10-15 | 2022-01-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Dnaアルキル化剤及びatr阻害剤を使用する併用療法 |
-
2021
- 2021-06-23 CA CA3183867A patent/CA3183867C/en active Active
- 2021-06-23 CN CN202180050401.6A patent/CN116635082A/zh active Pending
- 2021-06-23 TW TW110122959A patent/TW202216208A/zh unknown
- 2021-06-23 IL IL299368A patent/IL299368A/en unknown
- 2021-06-23 JP JP2022580316A patent/JP7793556B2/ja active Active
- 2021-06-23 AU AU2021298251A patent/AU2021298251A1/en active Pending
- 2021-06-23 WO PCT/IB2021/055548 patent/WO2021260579A1/en not_active Ceased
- 2021-06-23 MX MX2022016375A patent/MX2022016375A/es unknown
- 2021-06-23 BR BR112022026205A patent/BR112022026205A2/pt unknown
- 2021-06-23 US US18/012,705 patent/US20230330243A1/en active Pending
- 2021-06-23 KR KR1020237002457A patent/KR20230043109A/ko active Pending
- 2021-06-23 EP EP21736708.5A patent/EP4171650A1/en active Pending
-
2025
- 2025-12-17 JP JP2025258116A patent/JP2026048860A/ja active Pending